Advances in Optic Nerve Regeneration and Neuroprotection Strategies.
Liu Yang,Jing Zhang
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20120330
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:The most common irreversible blindness diseases are age-related macular degeneration, glaucoma, and diabetic retinopathy which involve the optic nerve or retina. These diseases share a common condition of causing blindness - progressive neural cells loss of retina (photoreceptor cells, retinal ganglion cells (RGCs)). Although many advances in the treatment for these diseases have been achieved in recent years, the visual function often cannot be reversed. To improve the visual outcomes, the retinal neuron cells must be rescued. Optic nerve diseases including glaucoma were mostly studied for the effort to rescue the injured neurons and regenerate the neuron axons. Optic nerve diseases include glaucoma, optic neuritis, and ischemic optic neuropathy. They are neurodegenerative diseases with progressive retinal ganglion cell death and consequential irreversible visual function damage. Taking glaucoma for example, it is defined as a progressive RGCs loss disease, which is traditionally treated with lowering intraocular pressure (IOP). We have realized the fact that lowering IOP alone fails to prevent the patients from visual field loss. New strategies have to be developed to rescue damaged RGCs. To rescue and preserve visual function, researches have been focused on all kinds of possible novel treatments using optic nerve regeneration and neuroprotection strategies. OPTIC NERVE REGENERATION Optic nerve regeneration means RGCs axons regeneration. There are four steps to overcome for successful optic nerve regeneration: RGCs must survive, survived RGCs must have the ability of axons growth, the axons must go all the way to the brain target and form the correct mapping, and the correct mapped axons must form stable synapse and preserve function. Optic nerve crush animal model was an ideal model used to investigate the RGCs injury and regeneration. There are two key problems to overcome: to enhance the intrinsic regeneration capability of adult RGCs, and to block the inhibition of the mature optic nerve environment. Enhancing the intrinsic growth capacity Many research papers have been published in different efforts to enhance the intrinsic RGCs regenerative ability. Cho et al found that Bcl-2 supported the intrinsic growth capacity of RGCs. Over expression of Bcl-2 and eliminating the astrocytes could promote the crushed optic nerve to regenerate axons. The optic nerve could regenerate in the optic nerve crush model in Bcl-2 transgenic mice on postnatal day 3, while the environment of central nervous system (CNS) was permissive for neuron growth. The regenerated axons went along optic tract pathways and reached the brain targets, although they predominantly innervated their ipsilateral brain targets.1,2 That was so far the longest way for RGCs regenerated axons growth. In addition, lithium protected RGCs and their axons through increasing Bcl-2 expression in optic nerve crush model.3,4 Providing neurotrophic factors is also an option to increase the RGCs growth capability. Neurotrophic factors including brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), glial cell line-derived neurotrophic factor, and nerve growth factor (NCF), make up a group of promising drugs to improve regeneration. Both injection of CNTF and Adeno-associated virus (AAV) delivering Fibroblast growth factor-2 (FGF-2) could increase axons regrowth.5 Moreover, activated macrophages could also promote RGCs axons extension by secreting proteins. LINGO-1 was identified as a new member of NgR1/p75 neurotrophin receptor, which prevented axonal regeneration recently. Besides, blocking LINGO-1 function it promoted retinal ganglion cell survival following ocular hypertension and optic nerve transection.6 Eliminating the growth inhibition in optic nerve environment Enhancing intrinsic growth capacity is not sufficient to support the optic nerve regeneration. There are many possible inhibitory factors in the mature CNS environment. The peripheral nerve has regenerative ability for its whole life. To improve the optic nerve regeneration, peripheral grafts were successfully inserted into the lesion site to form a bridge from the posterior eyeball to the brain target in the superior colliculus. Thus, multiple growth factors, especially Schwann cell derived factors, were supplied to enhance optic nerve regeneration.7 The most possible inhibitory factors are myelin- associated growth inhibitory protein and glial scarring. Oligodendrocytes degenerate and release myelin debris containing inhibitory proteins such as Nogo-A, myelin-associated glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (Omgp) at the site of injury.8 Astrocytes responding to injury could form glial scars and thus induce nerve growth inhibition. Those are barriers for optic nerve regeneration after optic nerve injury. Inhibiting astrocytes along with activating astrocytes is a more promising way to promote regeneration, which was verified in the adult mammalian CNS.1 To some extent, even a simple surgical injury of lens could improve optic nerve regeneration.9 Although many attempts have been carried out in optic nerve regeneration, there is still a long way to go to achieve successful connection to the brain target and functional recovery after RGCs injury. As there are so many difficulties in optic nerve regeneration, attempts to protect RGCs from death have emerged as promising methods. NEUROPROTECTION OF RGCS Neuroprotection therapy is designed to slow or prevent neuron death in neurodegenerative diseases. Experimental glaucoma model is mostly used to study the RGCs loss and neuroprotection. The strategies include providing neurotrophic factors, blocking toxicity pathway, anti- apoptosis of RGCs, stem cells implantation and so on. To explore the neuroprotective agents against glaucomatous neuron damage, the mechanism of neurodegeneration must be understood first. A number of neuroprotective strategies and drugs have been tested in various preclinical and clinical trials. In the last few years, many molecules have been tested as neuroprotective agents in experimental glaucoma, but only one clinical trial has documented the efficacy of a compound with neuroprotective and ICP lowering effect.10,11 Providing neurotrophic factors Application of exogenous neurotrophic factors (NTFs) prolongs RGCs-survival in vitro. The NTFs include brain derived neurotrophic factor (BDNF), ciliary derived neurotrophic factor (CNTF), neurotrophin-3, and neurotrophin-4. BDNF acts as a neurotrophin via extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K) pathway. NTF can activate Rho-A molecule and lessen the inhibition of axon regeneration through P75NTR and Nogo receptor. CNTF can increase RGCs survival through STAT3 and mitogen activated kinase pathway. Successful strategies may require a combination of neurotrophic factors such as basic fibroblast growth factor (bFGF), neurotrophin-3, and BDNF, palliating inhibition of axon regeneration, as well as promoting cells survival.12 Any neuroprotective effect after direct injection of neurotrophic factors into the eye is transient. Intravitreal injection of adeno-associated virus (AAV) or lentiviral vectors encoding BDNF or CNTF could prolong the neurotrophic factor effect for RGCs to a relatively longer period of time.13 A novel approach tested in vitro is the use of short peptides derived from activity-dependent neurotrophic factor and activity-dependent neurotrophic protein. In this case, most neurons maintained their nearly normal morphous, intact axons, and profuse synapse connections.14 Intravitreal injections of glial cell line-derived neurotrophic factor (GDNF)-loaded biodegradable microspheres had a certain level of neuroprotective effect.15 Transplanted oligodendrocyte precursor cells can also reduce neurodegeneration in a model of glaucoma after the activation of inflammatory stimulation.16 Additionally, transcorneal electrical stimulation could rescue axotomized retinal ganglion cells by activating endogenous retinal IGF-1 system.17 To sum up, a combination of neurotrophic factors and sustained releasing methods could achieve better results in neuroprotection. Blockade of receptors mediating excitotoxicity Menmantine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, works on blocking glutamate excitotoxicity. Memantine is the first drug approved for neuroprotection, although the primary result in glaucoma is not efficacy and still under testing.18 Probably the reason why menmantine didn't show protective effect in patients is that menmantine only protects a small part of RGCs and is unable to prevent the rest RGCs from apoptosis.19 Norrin plays a neuroprotective role for RGCs in NMDA-induced damage to the retina of mice. In eyes treated with Norrin, an increased retinal expression of leukemia inducible factor (LIF), endothelin-2 (Edn2) and the neuroprotective factors fibroblast growth factor-2 (FGF2), lens epithelium-derived growth factor (LEDGF), BDNF, and CNTF were detected.20 Glutamine release inhibitor factor riluzole can decrease the level of extracellular glutamine, thus contribute to neuroprotection. Lomerizine, asprin and an inhibitor of nitric oxide synthase can slow the loss of RGCs. Other drugs, such as eliprodil, L-kynurenine, LY354740 and ifenfrodil can also protect RGCs to a certain extent. Brimonidine is another neuroprotective drug, which is used as IOP-lowering agent. Novel delivery systems of brimonidine, which can reverse oxidative stress are under development and testing.18 In animal high IOP model, managing porphyrin, N-acetyl cysteine, astaxanthin, and CoQ10 could protect RCGs from injury. A-lipoic acid in rat ischemia model also showed neuroprotection effect. Other neuroprotective agents, which may act on one or more pathways of the neuron loss mechanism are under clinical trials. For example, a small interfering RNA- based caspase inhibitor is now tested on human non-arteritic ischemic optic neuropathy.18,21 Retinol and vitamin B1 can reduce the risk of open angle glaucoma in a prospective study of 3500 patients.22 A clinical trail of tocopherol (vitamin E) proved it could prevent visual field narrowing.23 Anti-apoptosis of RGCs In optic nerve degeneration disease, RGCs dies in an apoptotic way. Anti-apoptosis is a direct method to protect the RGCs. Bcl-2 family plays an important role in RGCs apoptosis. Drugs increasing the anti-apoptotic gene Bcl-2 and Bcl-x or decreasing the pro-apoptotic Bax has the neuroprotection effects. Cilostazol enhanced the survival of axotomized RGCs. Citicoline orally and by muscle injection could protect optic nerve in clinical tests through apoptosis-based pathway. While 5-S-GAD at low doses significantly attenuated the loss of RGCs induced by NMDA, probably through Bcl-2 system. TAT-mediated protein transduction demonstrated the effect of inhibition of neuronal apoptosis in vitro and in vivo. Autophagy is another form of programmed cell death except apoptosis. Activation of autophagy could induce retinal ganglion cell death. Despite this, rapamycin induced autophagy increased the number of surviving cells in optic nerve transection mice model, probably resulting from that rapamycin also preserved mitochondrial membrane potential and decreased intracellular reactive oxygen species production.24 Thus anti-autophagy should be another possible neuroprotective way in the future. Stem cell implantation Stem cells implantation is a promising strategy for neurodegenerative diseases. Photoreceptors, RPE cells, and RGCs can be replaced by stem cells and progenitor cells, although maintaining long-term function of the cells still need more studies. Embryonic stem-cell-derived cells injected into the vitreous in mouse eyes, whose RGCs were depleted by NMDA injection, could spread on the inner retina and express RGC markers, but failed to connect to the brain.25 In optic nerve transection model, müller cells could change into RGCs, while the procedure could be enhanced by controlling microglial reactivity with anti-inflammatory treatment.26 Hippocampus- derived neural stem cells are also used to implant into the eye and can partially differentiate to retinal neuronal like cells.27 There are progenitor cells, which can be manipulated towards RGCs in the ciliary body and within the retina. Generally, RGCs-like cells transplantation can provide more surviving RGCs, but rare cases showed RGCs axon growth. In summary, there are numerous researches on optic nerve regeneration and neuroprotection in rescuing the retinal neuron cells in neurodegenerative diseases. We searched on pubmed through these search terms, such as “retinal ganglion cell”, “optic nerve regeneration” and “neuroprotection”. Most of the studies showed promising results in the field of neuroprotection and optic nerve regeneration. Some drugs are under different stages of clinical trials. More studies are still needed in preventing, extenuating, and reversing the RGCs apoptosis. It is no doubt that neuroprotection and optic regeneration will be the most hopeful treatment strategy for neurodegenerative diseases like glaucoma in the near future.